Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ASPECTS OF LIPID-LOWERING THERAPY WITH ATORVASTATIN IN PATIENTS WITH MYOCARDIAL INFARCTION FROM THE PERSPECTIVE OF PERSONALIZED MEDICINE

https://doi.org/10.20996/1819-6446-2015-11-1-31-35

Full Text:

Abstract

Aim. To analyze the impact of the SLCO1B1*5 (c.521T> C) and LIPC (C514T) genes polymorphisms on the efficacy of atorvastatin therapy and the incidence of the combined endpoint in patients after myocardial infarction (MI).

Material and methods. 121 patients with MI aged 45-75 years were included into the study. All patients were prescribed atorvastatin. A group of 65 people in whom lipid levels were studied at baseline and after 3 months of atorvastatin treatment was formed to evaluate the efficacy of statin therapy. Genetic polimorphism of SLCO1B1*5 (c.521T> C) and LIPC (C514T) was determined using polimerase chain reaction. The prognosis was assessed by clinical outcomes after 3 months of follow-up, based on the achievement of the combined endpoint MACE (Major Adverse Cardiac Events), which included cardiovascular deaths, recurrent MI, hospitalization for progressive angina, unplanned coronary revascularization.

Results. Patients with SLCO1B1 c.521СC genotype had no significant reduction in the levels of atherogenic lipids (p>0.05), while patients with TT and TC genotypes demonstrated significant reduction in atherogenic cholesterol fractions (p<0.05). Allelic polymorphism of LIPC (C514T) gene has no influence on the atorvastatin treatment efficacy. The SLCO1B1 and LIPC (C514T) genes polymorphism has no impact on the three-month prognosis after MI.

Conclusion. The SLCO1B1 polymorphism should be taken into consideration while personalised prescribing of atorvastatin to patients with MI.

About the Authors

M. V. Solodun
Ryazan State Medical University
Russian Federation
Vysokovoltnaya ul. 9, Ryazan, 390026 Russia


S. S. Yakushin
Ryazan State Medical University
Russian Federation
Vysokovoltnaya ul. 9, Ryazan, 390026 Russia


References

1. Diagnosis and correction of lipid disorders for the prevention and treatment of atherosclerosis. Russian recommendations, V revision. Moscow 2012. Russian (Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации ,V пересмотр. Москва 2012).

2. Becquemont L., Alfirevic A., Amstutz U. et al. Pharmacogenomics. Practical recommendations for pharmacogenomics‐based prescription. ESF‐UB Conference on Pharmacogenetics and Pharmacogenomics 2010; 12(1): 113‐24.

3. Sychev D.A. Pharmacogenetic testing: clinical interpretation of the results. Moscow 2011: 25-6. Russian (Сычев Д.А. Фармакогенетическое тестирование: клиническая интерпретация результатов. Москва 2011: 25-6).

4. Pasanen M.K., Fredrikson H., Neuvonen P.J., Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007; 82(6): 726-33.

5. Pasanen M.K. Neuvonen M., Neuvonen P.J., Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16(12): 873-9.

6. Niemi M. Pasanen M.K., Neuvonen P.J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006; 80(4): 356-66.

7. Semenov A.V., Sichev D.A., Kukes V.G. Effect of genes SLCO1B1 andMDR1 polymorphismon atorvastatin pharmacokinetics and pharmacodynamics in patientswith primary hypercholesterolemia: results of pilot pharmacogenetics study. Racional'naja Farmakoterapija v Kardiologii 2008; 2: 47-50. Russian (Семенов А.В. , Сычев Д.А., Кукес В.Г. Влияние полиморфизма генов SLC01B1 и MDR1 на фармакокинетику и фармакодинамику аторвастатина у пациентов с первичной гиперхолестеринемией. Результаты пилотного фармакогенетического исследования. Рациональная Фармакотерапия в Кардиологии 2008; 2: 47-50).

8. Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004; 19(5): 375-80.

9. Zagorodnikova K.A., Nastas M.A., Topanova A.A., Shumkov V.A. Participation of genetic polymorphisms OATR1V1 521T> C and BCRP 421S> A in the individual efficacy and safety of statins. Сlinical Hospital 2013; 1(04): 63. Russian (Загородникова К.А., Настас М.А., Топанова А.А., Шумков В.А. Участие генетических полиморфизмов ОАТР1В1 521Т>С и BCRP 421С>A в индивидуальной эффективности и безопасности статинов. Клиническая больница 2013; 1(04): 63).

10. Hofman M.K., Princen H.M., Zwinderman A.H., Jukema J.W. Genetic variation in the rate-limiting enzyme in cholesterol catabolism (cholesterol 7alpha-hydroxylase) influences the progression of atherosclerosis and risk of new clinical events. Clin. Sci. (Lond) 2005; 108 (6): 539-545.

11. Rodrigues C. Alice, Perin Paula M.S., Purim Sheila G. et al. Pharmacogenetics of OATP Transporters Reveals That SLCO1B1c.388A>G Variant Is Determinant of Increased Atorvastatin Response. Int. J. Mol. Sci. 2011; 108: 5815-5827.

12. Search Collaborative Group, Link E, Parish S et al. SLCO1B1 variants and statin‐induced myopathy – a genomewide study. N. Engl. J. Med. 2008; 359(8): 789-799.

13. Zambon A, Deeb SS, Brown BG et al. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 2001; 103(6): 792-8.

14. Berk-Planken I.L, Hoogerbrugge N., Stolk R.P. et al. Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes. Effect of sex and the LIPC promoter variant. Diabetes Care 2003; 26: 427-432.

15. Zambon A., Hokanson J.E., Brown B.G., Brunzell J.D. Evidence for a new pathophysiological mevhanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999; 99: 1959-1964.

16. Vil'ms E.A., Dolgih T.I., Turchaninov D.V. The prevalence of polymorphisms of genes associated with socially significant multifactorial diseases in the population of Omsk. Medicinskij al'manah 2012; 22(3): 169-172. Russian (Вильмс Е.А., Долгих Т.И., Турчанинов Д.В. Распространенность полиморфизмов генов, ассоциированных с социально-значимыми мультифакторными заболеваниями, у населения г. Омска. Медицинский альманах 2012; 22(3): 169-172).


For citation:


Solodun M.V., Yakushin S.S. ASPECTS OF LIPID-LOWERING THERAPY WITH ATORVASTATIN IN PATIENTS WITH MYOCARDIAL INFARCTION FROM THE PERSPECTIVE OF PERSONALIZED MEDICINE. Rational Pharmacotherapy in Cardiology. 2015;11(1):31-35. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-1-31-35

Views: 632


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)